BiotechTube

Cinitapride + domperidone

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dyspepsia

Conditions

Dyspepsia

Trial Timeline

Oct 1, 2010 → Oct 1, 2011

NCT ID
NCT01355276

About Cinitapride + domperidone

Cinitapride + domperidone is a phase 3 stage product being developed by Eisai for Dyspepsia. The current trial status is completed. This product is registered under clinical trial identifier NCT01355276. Target conditions include Dyspepsia.

What happened to similar drugs?

3 of 15 similar drugs in Dyspepsia were approved

Approved (3) Terminated (3) Active (11)
🔄YM443Astellas PharmaPhase 3
🔄Z-338Zeria PharmaceuticalPhase 3
🔄Imonogas + EspumisanJohnson & JohnsonPhase 3
✅esomeprazoleAstraZenecaApproved
✅Esomeprazole MagnesiumAstraZenecaApproved
🔄TegaserodNovartisPhase 3
🔄TegaserodNovartisPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01355276Phase 3Completed

Competing Products

20 competing products in Dyspepsia

See all competitors
ProductCompanyStageHype Score
YH12852 0.1 mg + YH12852 0.25 mg + YH12852 0.5 mg + PlaceboYuhanPhase 2
27
YM443 + Placebo + MoxifloxacinAstellas PharmaPhase 1
29
YM443Astellas PharmaPhase 3
40
Rabeprazole + Rabeprazole + Rabeprazole + PlaceboEisaiPhase 2
35
Z-338Zeria PharmaceuticalPhase 3
40
Imonogas + EspumisanJohnson & JohnsonPhase 3
40
esomeprazoleAstraZenecaApproved
43
Esomeprazole MagnesiumAstraZenecaApproved
35
TegaserodNovartisPhase 3
40
TegaserodNovartisPhase 3
40
TegaserodNovartisPhase 3
40
Tegaserod and PlaceboNovartisApproved
35
TegaserodNovartisPhase 3
40
TegaserodNovartisPhase 3
40
Gabapentin + PlaceboPfizerPhase 3
32
Z-338Zeria PharmaceuticalPhase 2
35
Z-338Zeria PharmaceuticalPhase 2
35
Z-338Zeria PharmaceuticalPhase 2
35
Z-338 + PlaceboZeria PharmaceuticalPhase 3
40
Acotiamide hydrochloride hydrate + PlaceboZeria PharmaceuticalPhase 3
44